Literature DB >> 29777429

Review of clinical trial settings of drugs commonly used in primary care and approved between 2005 and 2012.

Jason R Crossley1, Tina P Tan2, Keisha Herbin Smith2, Joseph S Ross3,4,5, Daniel J Merenstein6.   

Abstract

Keywords:  FDA; Pivotal studies; Primary care

Mesh:

Year:  2018        PMID: 29777429      PMCID: PMC6108986          DOI: 10.1007/s11606-018-4486-7

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  6 in total

1.  Risk factors for adverse drug events among nursing home residents.

Authors:  T S Field; J H Gurwitz; J Avorn; D McCormick; S Jain; M Eckler; M Benser; D W Bates
Journal:  Arch Intern Med       Date:  2001-07-09

2.  Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.

Authors:  Nicholas S Downing; Jenerius A Aminawung; Nilay D Shah; Harlan M Krumholz; Joseph S Ross
Journal:  JAMA       Date:  2014 Jan 22-29       Impact factor: 56.272

3.  Comparison of diabetes care provided by an endocrinology clinic and a primary-care clinic.

Authors:  M C Leinung; A G Gianoukakis; D W Lee; S L Jeronis; J Desemone
Journal:  Endocr Pract       Date:  2000 Sep-Oct       Impact factor: 3.443

4.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

Authors:  David N Juurlink; Muhammad M Mamdani; Douglas S Lee; Alexander Kopp; Peter C Austin; Andreas Laupacis; Donald A Redelmeier
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

5.  Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox.

Authors:  Dennis T Ko; Muhammad Mamdani; David A Alter
Journal:  JAMA       Date:  2004-04-21       Impact factor: 56.272

6.  Publication of pivotal efficacy trials for novel therapeutic agents approved between 2005 and 2011: a cross-sectional study.

Authors:  James W Smithy; Nicholas S Downing; Joseph S Ross
Journal:  JAMA Intern Med       Date:  2014-09       Impact factor: 21.873

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.